INO-1001 is a novel PARP inhibitor, which is produced by Inotek Pharmaceuticals Corp. A lot of studies reveal its heartening functions in various disease models. Traumatic brain injury could induce the activity of PARP. After injury treatment with 10mg/kg/day INO-1001 could reduce the neurological deficit. This neurological recovery-promoting effects is highly related with the inhibition of PARP[1]. PARP inhibitors have protective function in ischemia-reperfusion injury models and cardiovascular diseases. For detecting the influence of PARP inhibitor for haemostatic parameters in vitro, INO-1001 was combined with different platelet aggregation inhibitors and fibrinolytic drug. The results showed that it could increase the effects of heparins above therapeutic ranges[2]. And in the clinical trials, INO-1001 has been approved by FDA to prevent prevent postoperative complications of aortic aneurysm repair. It also could protect the tissues from many damage such as ischemia. The safety and tolerance of INO-1001 has been proved in the phase I clinical trials. The other phase 2 clinical trial about INO-1001 is going on. In the recent research many parp inhibitors could prolong survival by blocking single-strand DNA repair in the BRCA mutant or deficient cancer cells. TheDNA breaking often cause by radiation and some chemotherapies. BRCA gene code the breast cancer type 1 susceptibility protein, which plays an important role in double strands breaking. The mutant of this functional gene would increase the risk for the hereditary breast-ovarian cancer syndrome, ovarian, fallopian tube, and prostate cancers for the accumulation of missense DNA in cells. Parp inhibitors make the cells without BRCA repair function sensitive, and kill them. BSI-201 could reduce 30% the tumor volume or stabilize the disease for several months in triple negative(ER, PR and HER2 deficient) breast cancer, which is a typical BRCA deficient cancer, in combination with gemcitabine and carboplatin inhibitor has many clinical benefits,with no significant difference in adverse events in phase2 trial. And the other parp inhibitor is AZD2281 (Olaparib). For those advanced breast tumor patients with BRCA mutations, it also prove itself good functions in these diseases. A-966492 is novel parp inhibitor ,which has a good potency against parp enzyme and cell. For parp-1 enzyme Ki value is 1nM,and for the cell assay the EC50 also is 1nM.In its chemical structure, benzimidazole carboxamide is the core structure. It has an excellent bioavailable activity, and could distribute into tumor tissue. In the xenograft model, it works very well in the triple negative breast cancer xenograft model both as a single agent and in combination with carboplatin. And the effect of Methazolastone (temozolomide), as an typical alkylating agent, could be enhanced by A-966492 in the B16F10 subcutaneous murine melanoma model. References: [1] Besson VC, et al. Brain Res. 2005 Apr 18;1041(2):149-56. [2] Tth O, et al. Life Sci. 2006 Jun 20;79(4):317-23. Epub 2006 Feb 9. Recent Articles: AG14361 enhances the chemotherapy agents activities PARP inhibitors has a great prospect for BRCA deficient cancer patients A novel member in parp inhibitors
Please Rate this Article 5 out of 54 out of 53 out of 52 out of 51 out of 5
Not yet Rated
